Status:

UNKNOWN

The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy

Lead Sponsor:

Kilimanjaro Clinical Research Institute

Collaborating Sponsors:

London School of Hygiene and Tropical Medicine

Ifakara Health Institute

Conditions:

Malaria Transmission

Eligibility:

All Genders

3-17 years

Phase:

PHASE4

Brief Summary

The investigators' Hypothesis is that "The correct timing of gametocytocidal drug in combination with an effective Artemisinin Combination Therapy can limit the infectiousness of malaria-infected indi...

Detailed Description

Global malaria elimination is back on the agenda, gametocytocidal drugs such as primaquine are currently advocated for use in the interventions that aim to interrupt malaria transmission and hence eli...

Eligibility Criteria

Inclusion

  • Age 3 years - 17 years
  • Residents of research area
  • Willingness to come for complete scheduled follow-up.
  • Uncomplicated malaria with P. falciparum mono-infection
  • Axillary temperature \> 37.5°C and \< 39.5°C, or history of fever in previous 48 hours.
  • No history of adverse reactions to study medication
  • Understanding of the procedures of the study by parent or guardian and willing to participate by signing written informed consent forms

Exclusion

  • Haemoglobin below 9g/dl
  • Inability to take drugs orally
  • Known hypersensitivity to any of the drugs given
  • Reported treatment with antimalarial chemotherapy in the past 2 weeks
  • Evidence of chronic disease or acute infection other than malaria
  • Domicile outside the study area
  • Signs of severe malaria( such as respiratory distress, altered consciousness deep breathing, anaemia)
  • Participating in other malaria studies conducted in the region
  • Mixed malaria parasite species infection
  • Positive pregnant test by Urine (UPT) if participant is female aged above 12 years
  • G6PD deficient using the fluorescence spot test

Key Trial Info

Start Date :

May 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2013

Estimated Enrollment :

250 Patients enrolled

Trial Details

Trial ID

NCT01906788

Start Date

May 1 2013

End Date

October 1 2013

Last Update

July 24 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Bagamoyo Research and Training Centre

Bagamoyo, Tanzania